High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer

Lung Cancer

Volumn 83, Issue 1, 2014, Pages 83-89

  Preusser, Matthias ^a,f   Berghoff, Anna S ^b,f   Berger, Walter ^c,f   Ilhan Mutlu, Aysegül ^a,f   Dinhof, Carina ^a,f   Widhalm, Georg ^a,f   Dieckmann, Karin ^a,f   Wöhrer, Adelheid ^b,f   Hackl, Monika ^d   von Deimling, Andreas ^e   Streubel, Berthold ^a,f   Birner, Peter ^a,f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Austrian National Cancer Registry   (Austria)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Central Nervous System Tumours Unit (CCC CNS)   (Austria)

Author keywords

Brain metastases; FGFR1; Fluorescent in situ hybridization; Gene amplification; Lung cancer

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; BRAIN METASTASIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIMARY TUMOR; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VISCERAL METASTASIS;

BRAIN METASTASES; FGFR1; FLUORESCENT IN SITU HYBRIDIZATION; GENE AMPLIFICATION; LUNG CANCER;

ADENOCARCINOMA; ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

EID: 84891738221     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.10.004     Document Type: Article

References (24)

1. Oxnard G.R., Binder A., Janne P.A. New targetable oncogenes in non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2013, 31:1097-1104.
2. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2010, 2:62ra93.
3. Zhang J., Zhang L., Su X., Li M., Xie L., Malchers F., et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:6658-6667.
4. Dutt A., Ramos A.H., Hammerman P.S., Mermel C., Cho J., Sharifnia T., et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 2011, 6:e20351.
5. Harding T.C., Long L., Palencia S., Zhang H., Sadra A., Hestir K., et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Science Translational Medicine 2013, 5:178ra139.
6. Lim S.M., Kim H.R., Shim H.S., Soo R.A., Cho B.C. Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. Future Oncology 2013, 9:377-386.
7. Drilon A., Rekhtman N., Ladanyi M., Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. The Lancet Oncology 2012, 13:e418-e426.
8. Yamanaka R. Medical management of brain metastases from lung cancer (Review). Oncology Reports 2009, 22:1269-1276.
9. Preusser M., Capper D., Ilhan-Mutlu A., Berghoff A.S., Birner P., Bartsch R., et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathologica 2012, 123:205-222.
10. Wohrer A., Waldhor T., Heinzl H., Hackl M., Feichtinger J., Gruber-Mosenbacher U., et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. Journal of Neuro-oncology 2009, 95:401-411.
11. Wolf J., LoRusso P., Camidge R., Perez J., Tabernero J., Hidalgo M., et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Research 2012, 72.
12. Guagnano V., Kauffmann A., Wohrle S., Stamm C., Ito M., Barys L., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discovery 2012, 2:1118-1133.
13. Preusser M., Berghoff A.S., Ilhan-Mutlu A., Magerle M., Dinhof C., Widhalm G., et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 2013.
14. Bender R., Lange S. Adjusting for multiple testing - when and howα. Journal of Clinical Epidemiology 2001, 54:343-349.
15. Goke F., Franzen A., Menon R., Goltz D., Kirsten R., Boehm D., et al. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 2012, 142:1020-1026.
16. Yang F., Zhang Y., Ressler S.J., Ittmann M.M., Ayala G.E., Dang T.D., et al. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Research 2013.
17. Rachagani S., Macha M.A., Ponnusamy M.P., Haridas D., Kaur S., Jain M., et al. MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis 2012, 33:1953-1964.
18. Tomlinson D.C., Baxter E.W., Loadman P.M., Hull M.A., Knowles M.A. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCgamma/COX-2-mediated mechanisms. PLoS ONE 2012, 7:e38972.
19. Zecchini S., Bombardelli L., Decio A., Bianchi M., Mazzarol G., Sanguineti F., et al. The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Molecular Medicine 2011, 3:480-494.
20. Suyama K., Shapiro I., Guttman M., Hazan R.B. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002, 2:301-314.
21. Freeman K.W., Gangula R.D., Welm B.E., Ozen M., Foster B.A., Rosen J.M., et al. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Research 2003, 63:6237-6243.
22. Sato T., Oshima T., Yoshihara K., Yamamoto N., Yamada R., Nagano Y., et al. Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncology Reports 2009, 21:211-216.
23. Fagel D.M., Ganat Y., Cheng E., Silbereis J., Ohkubo Y., Ment L.R., et al. Fgfr1 is required for cortical regeneration and repair after perinatal hypoxia. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2009, 29:1202-1211.
24. Preusser M., Berghoff A.S., Ilhan-Mutlu A., Magerle M., Dinhof C., Widhalm G., et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 2013, 80:278-283.